A potential vaccine against coronavirus infection company Moderna (USA) successfully tested on a small group of volunteers. This is stated in the article the results of research published July 14 in the journal The New England Journal of Medicine.
The study involved 45 persons aged from 18 to 55 years.
“The vaccine mRNA-1273 provoked the immune responses of all participants. In addition, there were no problems limiting testing”, – stated in the material. At the same time, half of the participants the vaccine caused side effects in mild or moderate degree, such as weakness, chills, headache, and pain at the injection site, Side effects that occurred in more than half of participants, included fatigue, chills, headache, myalgia and pain at the injection site, myalgia (muscle pain).
According to the portal Business Wire , citing the company’s CEO Stephen Bancel Moderna, at the end of July to begin the third phase of clinical trials of mRNA-1273.
Special medications from COVID-19 does not exist now in this disease is only symptomatic treatment. The world health organization notedthat a number of medicines can contribute to improved well-being and relief of symptoms COVID-19, but there is no evidence that any drug to prevent or treat the disease.
The head of the European Agency of medicines Marco Kavaleri previously reported that a vaccine for the coronavirus in the best case will be ready next year. May 15, U.S. President Donald trump suggested that the coronavirus vaccine can be developed and tested by the end of 2020.
According to who, currently about 120 trials of a vaccine against coronavirus SARS-COV-2 / COVID-19 worldwide. While 17 of the vaccines now have on the people.